个人简历

入选教育部“长江学者奖励计划”青年学者，基金委优秀青年科学基金获得者以及北京市科技新星。共发表SCI论文51篇（通讯作者12篇），其中回国后以通讯/第一作者在Nature Medicine、Nature Review Endocrinology、Cell Metabolism、Journal of Clinical Investigations和Gastroenterology等代谢领域权威期刊发表SCI论文15篇，获得国际专利1项。2016年作为课题负责人获得科技部国家重点研发计划精准医学专项的资助。目前担任中国生物物理学会代谢生物学分会副秘书长，中华医学会心血管分会代谢组委员，中国生物化学与分子会代谢专业委员会第一届委员会委员，以及美国生物化学与分子生物学学会(ASBMB)会员。

研究领域

基于功能代谢组学探讨代谢性疾病发病机制及其药物靶点

近期论文

1. Sun L, Xie C, Wang G, Wu Y, Wu Q, Wang X, Liu J, Deng Y, Xia J, Chen B, Zhang S, Yun C, Lian G, Zhang X, Zhang H, Bisson WH, Shi J, Gao X, Ge P, Liu C, Krausz KW, Nichols RG, Cai J, Rimal B, Patterson AD, Wang X, Gonzalez FJ, Jiang CT*. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nat Med. In press.
2. Gonzalez FJ*, Xie C, Jiang CT*. The role of hypoxia-inducible factors in metabolic diseases. Nat Rev Endocrinol.2018 Oct 1. doi: 10.1038/s41574-018-0096-z. [Epub ahead of print]
3. Zhang SY, Dong YQ, Wang P, Zhang X, Yan Y, Sun L, Liu B, Zhang D, Zhang H, Liu H, Kong W, Hu G, Shah YM, Gonzalez FJ, Wang X*,Jiang CT*. Adipocyte-derived lysophosphatidylcholine activates adipocyte and adipose tissue macrophage nod-like receptor protein 3 inflammasomes mediating homocysteine-induced insulin resistance. EBioMedicine. 2018 May;31:202-216.
4. Xie C, Yagai T, Luo Y, Liang X, Chen T, Wang Q, Sun D, Zhao J, Ramakrishnan SK, Sun L, Jiang C, Xue X, Tian Y, Krausz KW, Patterson AD, Shah YM, Wu Y*, Jiang CT*, Gonzalez FJ*. Activation of intestinal hypoxia-inducible factor 2α during obesity contributes to hepatic steatosis. Nat Med. 2017 Nov;23(11):1298-1308.
5. Hao HH#, Cao LJ#, Jiang CT#, Che Y, Zhang SY, Takahashi S, Wang GJ*, Gonzalez FJ*. Farnesoid X receptor regulation of the NLRP3 inflammasome underlies cholestasis-associated sepsis. Cell Metab. 2017 Apr 4;25(4):856-867.
6. Xie C, Jiang CT*, Shi J, Gao X, Sun D, Sun L, Wang T, Takahashi S, Anitha M,Krausz KW, Patterson AD, Gonzalez FJ*. An intestinal farnesoid X receptor-ceramide signaling axis modulates hepatic gluconeogenesis in mice. Diabetes. 2017 Mar;66(3):613-626.
7. Lv Y, Zhang SY, Liang XY, Zhang H, Xu Z, Liu B, Xu MJ, Jiang CT*, Shang J*, Wang X. Adrenomedullin 2 enhances beiging in white adipose tissue directly in adipocyte-autonomous manner and indirectly through activation of M2 macrophages. J Biol Chem. 2016 Nov 4;291(45):23390-23402.
8. Gonzalez FJ*, Jiang CT*, Patterson AD. An intestinal microbiota-farnesoid X receptor axis modulates metabolic disease. Gastroenterology. 2016 Nov;151(5):845-859.
9. Zhang SY, Lv Y, Zhang H, Wang T, Feng J, Wang Y, Liu G, Xu MJ, Wang X*, Jiang CT*. Adrenomedullin 2 improves early obesity-induced adipose insulin resistance by inhibiting the class II major histocompatibility complex in adipocytes. Diabetes. 2016 Aug;65(8):2342-55.
10. Pang Y, Li Y, Lv Y, Sun L, Zhang SY, Li Y, Wang Y, Liu G, Xu MJ, Wang X*, Jiang CT*. Intermedin restores hyperhomocysteinemia-induced macrophage polarization and improves insulin resistance in mice. J Biol Chem. 2016 Jun 3;291(23):12336-45.
11. Jiang CT, Xie C, Lv Y, Li J, Krausz KW, Shi J, Brocker CN, Desai D, Amin SG, Bisson W, Liu Y, Gavrilova O, Patterson AD, Gonzalez FJ. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun. 2015 Dec 15; 6:10166.
12. Jiang CT, Xie C, Li F, Zhang LM, Nichols RG, Krausz KW, Cai J, Qi YP, Fang ZZ, Takahashi S, Tanaka N, Desai D, Amin S, Albert I, Patterson AD*, Gonzalez FJ*. Intestinal farnesoid X receptor signaling promotes non-alcoholic fatty liver disease. J Clin Invest. 2015 Jan;125(1):386-402.